Canada Europe Joint Funding Initiative
Must include a strong collaboration between at least one research entity (academic or private) in Canada and at least one private entity in Alsace and/or Rhone-Alpes.
Maximum $700,000 in Canada and equivalent in France.
- A research agreement must be signed by all research entities involved in the project within 3 months after the funding confirmation.
- Intellectual property generated under this funding program will be managed according to the policies of the financial partners involved.
- A licence option will be granted to the CQDM industrial sponsors (currently Merck and Pfizer and their subsidiaries) for the use of the results for R&D purposes only. The main conditions of the end user license option will be negotiated before the beginning of the project and will take into account pre- existing IP as well as contribution from each party.
- CDQM industrial sponsors will have no rights to commercialize the IP resulting from the project or the pre-existing IP.
If applying for a full proposal please send a copy along with a signed OR5 form to the Research Services email address at firstname.lastname@example.org two weeks in advance of the date you intend to submit externally. It is not necessary to submit your letter of intent internally.
The Canada/France Program is open all year long. Candidates can submit letters of intent any time, by using the form available on the Call for Proposals. Full proposals are by invitation only.
How to Apply
Please refer to the Phase 1 application and Final Selection information and forms.
- Include strong collaboration between at least one research entity (public or private) in Canada and at least one private entity in Alsace and/or Rhone-Alpes. Please note that in Alsace and/or Rhone-Alpes, only private entities are eligible to apply. In Canada the participation of a private organization is highly encouraged and preferred, but not mandatory.
- Generate clear deliverables with immediate applications in the drug discovery and/or development process of new drugs.
- Be highly innovative with a strong and wide potential impact on biopharmaceutical research.
- When an SME is involved, be aligned with the business plan and have an impact on its corporate objectives.